Meta Information

ID:l-ergothioneine

Name:L-Ergothioneine

Schema Version:2.4_uniform_evidence_2026_06_18

Created

2026-07-02T07:04:55Z

Model

phase-b-newfiles-claude-opus-4.8

Interactions

Target id:

/class/chemotherapy-radiation

Target name:

Chemotherapy / radiation

Severity:

minor

Interaction type:

diminishing

Nature:

relative

Temporal spacing:

Hours before target:

0

Hours after target:

0

Description:

As an antioxidant that accumulates in cells, ergothioneine could theoretically blunt ROS-dependent cancer therapies.

Actionable advice:

It is a good idea to talk to an oncologist before use during chemo/radiation; evidence is limited.

Validation status:

validated_via_class_inference

Evidence tier:

tier_c

Evidence basis:

class_inference_summary

Evidence anchors:

Source url:

Established mechanism / class pharmacology (no single primary source quoted)

Exact phrase from label:

Ergothioneine is a cytoprotective antioxidant; theoretical interference with ROS-dependent therapy. Low-certainty.

Label source:

Class inference

Action type:

monitor